T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma

Blood Adv. 2019 Oct 8;3(19):2812-2815. doi: 10.1182/bloodadvances.2019000600.

Abstract

  1. T cells from patients early in myeloma therapy exhibit better fitness for CAR T manufacturing than those from relapsed/refractory patients.

  2. CAR T cells may be more effective if manufactured from patients before onset of relapsed/refractory disease.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Humans
  • Middle Aged
  • Multiple Myeloma / genetics*
  • Phenotype
  • Receptors, Chimeric Antigen / metabolism*

Substances

  • Receptors, Chimeric Antigen